0.00%
21.05%
38.55%
66.67%
36.90%
15.58%
-68.14%
AI Spotlight on AKBA
Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc.has collaboration agreements with Otsuka Pharmaceutical Co. Ltd.for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.
The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 2.3 |
| Change Percentage | 0.00% |
| Open | 2.3 |
| Previous Close | 2.3 |
| Market Cap ( Millions) | 502 |
| Volume | 1091090 |
| Year High | 2.48 |
| Year Low | 0.8 |
| M A 50 | 1.97 |
| M A 200 | 1.49 |
Financial Ratios
| FCF Yield | -7.67% |
| Dividend Yield | 0.00% |
| ROE | 129.56% |
| Debt / Equity | -96.39% |
| Net Debt / EBIDTA | 279.02% |
| Price To Book | -9.6 |
| Price Earnings Ratio | -10.52 |
| Price To FCF | -13.03 |
| Price To sales | 2.95 |
| EV / EBITDA | 98.94 |
News
- Jan -13 - Akebia Therapeutics Announces Multiple Positive Business Updates
- Jan -03 - New Strong Sell Stocks for January 3rd
- Jan -02 - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -18 - Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -05 - New Strong Sell Stocks for December 5th
- Dec -03 - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -03 - U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
- Nov -27 - New Strong Sell Stocks for November 27th
- Nov -25 - Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
- Nov -22 - New Strong Sell Stocks for November 22nd
- Nov -20 - Q3 2024 Earnings: Hold Akebia Therapeutics
- Nov -14 - Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
- Nov -12 - Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
- Nov -07 - Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
- Nov -07 - Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
- Nov -07 - Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov -01 - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -01 - Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
- Oct -22 - Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
- Oct -15 - Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapeutics
Expected Growth : 8.97 %
What the company do ?
Akebia Therapeutics' Novel Therapeutics is a pipeline of investigational medicines, including vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia treatment.
Why we expect these perspectives ?
Akebia Therapeutics' Novel Therapeutics segment growth of 8.97% is driven by increasing adoption of Vadadustat, a novel oral therapy for anemia in chronic kidney disease patients. Strong clinical trial results, expanding commercial presence, and growing demand for innovative treatments in the nephrology space contribute to this growth.
Akebia Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Auryxia | An oral tablet formulation of ferric citrate, a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. |
| Feraheme | An intravenous iron replacement therapy for the treatment of iron deficiency anemia in adult patients with CKD. |
Akebia Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Akebia Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments for anemia and other diseases. However, the company's innovative products and strong R&D pipeline mitigate this threat to some extent.
Bargaining Power Of Customers
Akebia Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers. The company's products are often reimbursed by insurance companies, which reduces the bargaining power of customers.
Bargaining Power Of Suppliers
Akebia Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services. However, the company's dependence on a few key suppliers for certain components increases the bargaining power of suppliers.
Threat Of New Entrants
Akebia Therapeutics, Inc. faces a high threat of new entrants due to the growing demand for innovative treatments and the presence of several biotech companies with similar product pipelines. The company's strong intellectual property portfolio and regulatory approvals mitigate this threat to some extent.
Intensity Of Rivalry
Akebia Therapeutics, Inc. operates in a highly competitive industry with several established players and new entrants. The company faces intense rivalry from companies such as Amgen, Johnson & Johnson, and Pfizer, which have strong product pipelines and marketing capabilities.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 147.31% |
| Debt Cost | 5.79% |
| Equity Weight | -47.31% |
| Equity Cost | 8.61% |
| WACC | 4.45% |
| Leverage | -311.39% |
Akebia Therapeutics, Inc. : Quality Control
Akebia Therapeutics, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
